Djaldetti M, Leibovitch C, Ganelin _Cohen E, Bessler H (2019) Rituximab Modifies Peripheral Blood Mononuclear Cells Immune Responses. Int J Immunol Immunother 6:037.


© 2019 Djaldetti M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

RESEARCH ARTICLE | OPEN ACCESSDOI: 10.23937/2378-3672/1410037

Rituximab Modifies Peripheral Blood Mononuclear Cells Immune Responses

Meir-Djaldetti, MD1, Chyia-Leibovitch, MD2, Esther-Ganelin-Cohen, MD, PhD3 and Hanna-Bessler, PhD1*

1Laboratory for Immunology and Hematology Research, Rabin Medical Center, Hasharon Hospital, The Sackler School of Medicine, Tel-Aviv University, Israel

2Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, The Sackler School of Medicine, Tel-Aviv University, Israel

3Institute of Pediatric Neurology, Schneider Children's Medical Center of Israel, The Sackler School of Medicine, Tel-Aviv University, Israel



Rituximab, the monoclonal antibody against B lymphocyte protein CD20, is a major asset for treatment of diseases in which B CD20 cells are the foremost etiologic culprit. Based on observations that rituximab is capable to modulate immune responses the question if the drug may affect the capacity of human peripheral blood mononuclear cells (PBMC) for cytokine production was posed.


PBMC were incubated without or with various concentrations of rituximab and the production of TNFα, IL-1β, IL-6, IFNγ, IL-2, IL-1ra and IL-10 was examined using the ELISA method.


While rituximab did not impel non-stimulated PBMC to produce any of the cytokines examined, cells stimulated with PMA/ionomycin expressed a concentration-dependent inhibition of the pro-inflammatory cytokines IL-2 and IFNγ. Following LPS stimulation the secretion of TNFα was slightly increased. Notably, the production of the anti-inflammatory cytokine IL-10 was restrained, but at lesser extend in comparison to the effect of rituximab on the pro-inflammatory cytokine secretion.


The results indicate that rituximab in addition to its efficacy as an antibody against CD20 receptor expressing cells, 'exerts immunomodulatory activity by targeting their capacity for inflammatory cytokine production.